Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its target price lowered by HC Wainwright from $43.00 to $29.00 in a report issued on Monday, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Allogene Therapeutics' Q4 2022 earnings at ($0.77) EPS, FY2022 earnings at ($2.44) EPS, Q1 2023 earnings at ($0.70) EPS, Q2 2023 earnings at ($0.73) EPS, Q3 2023 earnings at ($0.76) EPS, Q4 2023 earnings at ($0.79) EPS and FY2023 earnings at ($3.00) EPS.
A number of other equities analysts also recently commented on the stock. Raymond James downgraded shares of Allogene Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, August 10th. B. Riley dropped their price target on shares of Allogene Therapeutics from $21.00 to $18.00 and set a buy rating on the stock in a research report on Thursday, September 22nd. Truist Financial dropped their price target on shares of Allogene Therapeutics to $29.00 in a research report on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Allogene Therapeutics to $32.00 in a research report on Thursday, October 13th. Finally, JMP Securities reaffirmed a buy rating and set a $23.00 target price on shares of Allogene Therapeutics in a research note on Tuesday, September 27th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $25.70.
Get
Allogene Therapeutics alerts:
Allogene Therapeutics Stock Down 0.9 %
Shares of ALLO opened at $10.60 on Monday. The company has a 50-day simple moving average of $10.50 and a 200-day simple moving average of $11.42. The company has a market capitalization of $1.53 billion, a PE ratio of -4.82 and a beta of 0.59. Allogene Therapeutics has a 52-week low of $6.43 and a 52-week high of $19.25.
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net
margin of 126,580.16% and a negative return on equity of 37.74%. During the same quarter in the previous year, the company posted ($0.57) EPS. On average, research analysts anticipate that Allogene Therapeutics will post -2.38 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Impact Advisors LLC boosted its stake in Allogene Therapeutics by 24.5% in the 3rd quarter. Capital Impact Advisors LLC now owns 19,539 shares of the company's stock valued at $196,000 after purchasing an additional 3,839 shares during the period. Balyasny Asset Management LLC bought a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $448,000. BNP Paribas Arbitrage SNC grew its position in shares of Allogene Therapeutics by 816.8% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 288,390 shares of the company's stock valued at $3,115,000 after buying an additional 256,934 shares during the last quarter. State Street Corp boosted its position in shares of Allogene Therapeutics by 18.1% during the 3rd quarter. State Street Corp now owns 6,680,297 shares of the company's stock valued at $72,147,000 after purchasing an additional 1,025,973 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at about $561,000. 84.81% of the stock is currently owned by institutional investors.
About Allogene Therapeutics
(Get Rating)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
Featured Stories
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
